» Articles » PMID: 28509327

The Occurrence of Hepatocellular Carcinoma in Different Risk Stratifications of Clinically Noncirrhotic Nonalcoholic Fatty Liver Disease

Overview
Journal Int J Cancer
Specialty Oncology
Date 2017 May 17
PMID 28509327
Citations 43
Authors
Affiliations
Soon will be listed here.
Abstract

Nonalcoholic fatty liver disease (NAFLD) may be a cause of hepatocellular carcinoma (HCC), but its high prevalence challenges current surveillance strategies. We aimed to evaluate HCC incidences in different risk stratifications for noncirrhotic NAFLD. Using Taiwan's National Health Insurance Research Database, we located 31,571 patients with NAFLD between the years 1998 and 2012. After excluding other causes of hepatitis, underlying cirrhosis or malignancy, 18,080 patients were recruited for final analysis. Cumulative incidences of HCC were analyzed after adjusting for competing mortality. With a median follow-up duration of 6.32 years in the study cohort, the 10-year cumulative incidence of HCC was 2.73% [95% confidence interval (CI): 1.69-3.76%]. Hepatoprotectant was used as a surrogate marker for elevated serum alanine transaminase (ALT). After adjusting for age, gender, hypertension, hypercholesterolemia, diabetes mellitus, gout, statin use, metformin use and aspirin use, elevated ALT was independently associated with an increased HCC risk [hazard ratio (HR) 6.80, 95% CI: 3.00-15.42; p < 0.001]. Multivariate stratified analysis verified this association in all subgroups (HR> 1.0). Moreover, increased age (HR 1.08 per year, 95% CI: 1.05-1.11) and statin use (HR 0.29, 95% CI: 0.12-0.68) were also identified as independent risk factors. The 10-year cumulative HCC incidence was highest in older (age >55 years) patients with ALT elevation (12.41%, 95% CI: 5.99-18.83%), but lowest in younger patients without ALT elevation (0.36%, 95% CI: 0-1.08%). The incidence of HCC was relatively low in patients with clinically noncirrhotic NAFLD, however, HCC risk was significantly increased in older patients experiencing an elevated serum ALT.

Citing Articles

Statins decrease the risk of hepatocellular carcinoma in metabolic dysfunction-associated steatotic liver disease: A systematic review and meta-analysis.

Tarar Z, Farooq U, Inayat F, Basida S, Ibrahim F, Gandhi M World J Exp Med. 2024; 14(4):98543.

PMID: 39713070 PMC: 11551700. DOI: 10.5493/wjem.v14.i4.98543.


Risk factors of hepatocellular carcinoma associated with nonalcoholic fatty liver disease: Systematic review and meta-analysis.

Yin H, Yan Z, Zhao F Technol Health Care. 2024; 32(6):3943-3954.

PMID: 39269862 PMC: 11613056. DOI: 10.3233/THC-231331.


A review of MASLD-related hepatocellular carcinoma: progress in pathogenesis, early detection, and therapeutic interventions.

Ma Y, Wang J, Xiao W, Fan X Front Med (Lausanne). 2024; 11:1410668.

PMID: 38895182 PMC: 11184143. DOI: 10.3389/fmed.2024.1410668.


Endotoxemia and Platelets: 2 Players of Intrahepatic Microthrombosis in NAFLD.

Violi F, Pastori D, Pignatelli P, Cammisotto V JACC Basic Transl Sci. 2024; 9(3):404-413.

PMID: 38559621 PMC: 10978333. DOI: 10.1016/j.jacbts.2023.07.003.


Statin Use and Liver Cancer Risk: A Meta-Epidemiological Study of Retrospective Cohort Studies by the Types of Constructed Cohort.

Bae J Asian Pac J Cancer Prev. 2024; 25(3):777-783.

PMID: 38546060 PMC: 11152385. DOI: 10.31557/APJCP.2024.25.3.777.